TScan Therapeutics Public
TScan Therapeutics is a biopharmaceutical company that specializes in developing immunotherapy treatments for cancer. Their main focus is on T-cell receptor (TCR) engineered T cell therapies (TCR-T) for patients with cancer. Their lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are being developed to eliminate residual leukemia and prevent relapse after stem cell transplantation. Additionally, TScan is working on developing multiplexed TCR-T therapy candidates for the treatment of solid tumors. Their goal is to provide innovative and effective treatments for cancer patients.
Connections from
Industry:
Stem Cells (Regenerative Medicine)
Last Funding Type:
Series C
Headquarters:
Waltham, Massachusetts, United States
Founded Date:
2018-01-01
Funding Status:
IPO
Total Funding:
137500000
Employee Number:
154